Abdominal Pain News and Research RSS Feed - Abdominal Pain News and Research

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.
Researchers develop noninvasive method to detect kidney cancer early

Researchers develop noninvasive method to detect kidney cancer early

If kidney cancer is diagnosed early — before it spreads — 80 percent of patients survive. However, finding it early has been among the disease's greatest challenges. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. [More]
Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI. [More]
Study: Cancer drug may help reduce bleeding in HHT patients

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia. [More]
Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. [More]
Peanut consumption in infancy prevents allergy in kids who are at high-risk for developing peanut allergy

Peanut consumption in infancy prevents allergy in kids who are at high-risk for developing peanut allergy

A new study reported today in the New England Journal of Medicine demonstrates that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy. [More]
Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announced today results from a new European survey that revealed more than 9 out of 10 people with ulcerative colitis (UC) have low to medium adherence to their medication, putting them at five times greater risk of relapse. [More]
Two diagnostic tests can help identify children who require surgical treatment for appendicitis

Two diagnostic tests can help identify children who require surgical treatment for appendicitis

Data from two standard diagnostic tests commonly obtained in children evaluated for abdominal pain--when combined--can improve the ability of emergency department physicians and pediatric surgeons to identify those patients who should be sent to the operating room for prompt removal of an inflamed appendix; those who may be admitted for observation; and those who may safely be discharged home, according to a new study published online as an "article in press" in the Journal of the American College of Surgeons. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Astute Medical previews upcoming AKI & CRRT 2015 conference to be held in San Diego

Astute Medical previews upcoming AKI & CRRT 2015 conference to be held in San Diego

Astute Medical, Inc., developer of the NephroCheck® Test, today previewed the upcoming AKI & CRRT 2015 conference to be held in San Diego from February 17 to February 20. [More]
Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism. [More]
Temple University Hospital participating in trial to test vibrating capsule for chronic constipation treatment

Temple University Hospital participating in trial to test vibrating capsule for chronic constipation treatment

Chronic constipation is a common problem that affects approximately 15 percent of the U.S. population, according to the American Gastroenterological Association. It can be painful and lead to a reduction in a patient's quality of life. Temple University Hospital is the only hospital in the Philadelphia region participating in a nationwide clinical trial to test an innovative, vibrating capsule for patients with chronic constipation. [More]
Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

bioMérieux, a world leader in the field of in vitro diagnostics, and Astute Medical, Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers, today announced that they have signed a global, semi-exclusive agreement regarding the development of a test for the early risk assessment of acute kidney injury (AKI). [More]
British scientists take major initiative to tackle Crohn's disease

British scientists take major initiative to tackle Crohn's disease

British scientists are playing a key role in a global quest to find the causes of an incurable bowel condition. [More]
QDREC software may help find effective treatment for schistosomiasis

QDREC software may help find effective treatment for schistosomiasis

For decades, scientists around the world have worked to develop a treatment for schistosomiasis, a debilitating water-born parasite that affects more than 200 million people worldwide. To aid this research, Rahul Singh, professor of computer science at San Francisco State University, has developed software that solves the key challenge of quantitatively assessing the impact of a drug on the parasite. [More]
Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Advertisement